Battleground

Chronic kidney disorders mineral and bone disease - Calcium obsession, vitamin D, and binder confusion

Csaba Kovesdy, Rajnish Mehrotra, Kamyar Kalantar-Zadeh

Research output: Contribution to journalShort survey

38 Citations (Scopus)

Abstract

Renal osteodystrophy is a significant complication in chronic kidney disease. This condition is referred to as mineral and bone disorders in chronic kidney disease, mainly because of its wider ranging impact, including an association with increased mortality and non-bone-related morbidity. Because most of the abnormalities that characterize mineral and bone disorders in chronic kidney disease (e.g., hyperphosphatemia, secondary hyperparathyroidism) are amenable to therapeutic interventions, this field has also been in the cross-hairs of many pharmaceutical companies. The advent of a number of new therapeutic options for mineral and bone disorders in chronic kidney disease has broadened our armamentarium but has also resulted in an intense marketing battle between pharmaceutical companies. The paucity of randomized, controlled trials in this field has allowed the various companies to promote unilaterally data that fit their needs and to attempt to discredit data that support their competitors' products. Although this attitude is expected and regarded as acceptable in a consumer society, on a scientific level, it has resulted in a polarized and often confused audience: The practicing nephrologists. This article provides a historical overview of how the field of mineral and bone disorders in chronic kidney disease has evolved from a pharmaceutical standpoint, with a critical emphasis of the key moments that resulted in the current acrimonious climate. Also assessed is what the key unanswered questions are in this field, and practical solutions to the discussed issues are provided.

Original languageEnglish (US)
Pages (from-to)168-173
Number of pages6
JournalClinical Journal of the American Society of Nephrology
Volume3
Issue number1
DOIs
StatePublished - Jan 1 2008

Fingerprint

Chronic Kidney Disease-Mineral and Bone Disorder
Obsessive Behavior
Confusion
Vitamin D
Calcium
Pharmaceutical Preparations
Hyperphosphatemia
Secondary Hyperparathyroidism
Marketing
Climate
Chronic Renal Insufficiency
Hair
Randomized Controlled Trials
Morbidity
Mortality
Therapeutics

All Science Journal Classification (ASJC) codes

  • Epidemiology
  • Critical Care and Intensive Care Medicine
  • Nephrology
  • Transplantation

Cite this

Battleground : Chronic kidney disorders mineral and bone disease - Calcium obsession, vitamin D, and binder confusion. / Kovesdy, Csaba; Mehrotra, Rajnish; Kalantar-Zadeh, Kamyar.

In: Clinical Journal of the American Society of Nephrology, Vol. 3, No. 1, 01.01.2008, p. 168-173.

Research output: Contribution to journalShort survey

@article{62b57ffc93894306b19bcb7553c7059d,
title = "Battleground: Chronic kidney disorders mineral and bone disease - Calcium obsession, vitamin D, and binder confusion",
abstract = "Renal osteodystrophy is a significant complication in chronic kidney disease. This condition is referred to as mineral and bone disorders in chronic kidney disease, mainly because of its wider ranging impact, including an association with increased mortality and non-bone-related morbidity. Because most of the abnormalities that characterize mineral and bone disorders in chronic kidney disease (e.g., hyperphosphatemia, secondary hyperparathyroidism) are amenable to therapeutic interventions, this field has also been in the cross-hairs of many pharmaceutical companies. The advent of a number of new therapeutic options for mineral and bone disorders in chronic kidney disease has broadened our armamentarium but has also resulted in an intense marketing battle between pharmaceutical companies. The paucity of randomized, controlled trials in this field has allowed the various companies to promote unilaterally data that fit their needs and to attempt to discredit data that support their competitors' products. Although this attitude is expected and regarded as acceptable in a consumer society, on a scientific level, it has resulted in a polarized and often confused audience: The practicing nephrologists. This article provides a historical overview of how the field of mineral and bone disorders in chronic kidney disease has evolved from a pharmaceutical standpoint, with a critical emphasis of the key moments that resulted in the current acrimonious climate. Also assessed is what the key unanswered questions are in this field, and practical solutions to the discussed issues are provided.",
author = "Csaba Kovesdy and Rajnish Mehrotra and Kamyar Kalantar-Zadeh",
year = "2008",
month = "1",
day = "1",
doi = "10.2215/CJN.03850907",
language = "English (US)",
volume = "3",
pages = "168--173",
journal = "Clinical journal of the American Society of Nephrology : CJASN",
issn = "1555-9041",
publisher = "American Society of Nephrology",
number = "1",

}

TY - JOUR

T1 - Battleground

T2 - Chronic kidney disorders mineral and bone disease - Calcium obsession, vitamin D, and binder confusion

AU - Kovesdy, Csaba

AU - Mehrotra, Rajnish

AU - Kalantar-Zadeh, Kamyar

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Renal osteodystrophy is a significant complication in chronic kidney disease. This condition is referred to as mineral and bone disorders in chronic kidney disease, mainly because of its wider ranging impact, including an association with increased mortality and non-bone-related morbidity. Because most of the abnormalities that characterize mineral and bone disorders in chronic kidney disease (e.g., hyperphosphatemia, secondary hyperparathyroidism) are amenable to therapeutic interventions, this field has also been in the cross-hairs of many pharmaceutical companies. The advent of a number of new therapeutic options for mineral and bone disorders in chronic kidney disease has broadened our armamentarium but has also resulted in an intense marketing battle between pharmaceutical companies. The paucity of randomized, controlled trials in this field has allowed the various companies to promote unilaterally data that fit their needs and to attempt to discredit data that support their competitors' products. Although this attitude is expected and regarded as acceptable in a consumer society, on a scientific level, it has resulted in a polarized and often confused audience: The practicing nephrologists. This article provides a historical overview of how the field of mineral and bone disorders in chronic kidney disease has evolved from a pharmaceutical standpoint, with a critical emphasis of the key moments that resulted in the current acrimonious climate. Also assessed is what the key unanswered questions are in this field, and practical solutions to the discussed issues are provided.

AB - Renal osteodystrophy is a significant complication in chronic kidney disease. This condition is referred to as mineral and bone disorders in chronic kidney disease, mainly because of its wider ranging impact, including an association with increased mortality and non-bone-related morbidity. Because most of the abnormalities that characterize mineral and bone disorders in chronic kidney disease (e.g., hyperphosphatemia, secondary hyperparathyroidism) are amenable to therapeutic interventions, this field has also been in the cross-hairs of many pharmaceutical companies. The advent of a number of new therapeutic options for mineral and bone disorders in chronic kidney disease has broadened our armamentarium but has also resulted in an intense marketing battle between pharmaceutical companies. The paucity of randomized, controlled trials in this field has allowed the various companies to promote unilaterally data that fit their needs and to attempt to discredit data that support their competitors' products. Although this attitude is expected and regarded as acceptable in a consumer society, on a scientific level, it has resulted in a polarized and often confused audience: The practicing nephrologists. This article provides a historical overview of how the field of mineral and bone disorders in chronic kidney disease has evolved from a pharmaceutical standpoint, with a critical emphasis of the key moments that resulted in the current acrimonious climate. Also assessed is what the key unanswered questions are in this field, and practical solutions to the discussed issues are provided.

UR - http://www.scopus.com/inward/record.url?scp=38749153987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38749153987&partnerID=8YFLogxK

U2 - 10.2215/CJN.03850907

DO - 10.2215/CJN.03850907

M3 - Short survey

VL - 3

SP - 168

EP - 173

JO - Clinical journal of the American Society of Nephrology : CJASN

JF - Clinical journal of the American Society of Nephrology : CJASN

SN - 1555-9041

IS - 1

ER -